Analyst: Illumina's Takeover Clock Ticking

Apr 20, 2012

One year. That's how long Illumina CEO Jay Flatley has to prove he can increase his company's value beyond Roche's $6.7 billion takeover bid, Maxim Group analyst Bryan Brokmeier tells Bloomberg.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Breaking News

The Scan

Shift to New Variant Work

Imperial College London researchers are shifting away from testing a COVID-19 vaccine to focus on combating newly emerging SARS-CoV-2 variants, the Independent says.

Victim Identified with Genetic Genealogy

According to the Associated Press, genetic genealogy has helped law enforcement officials identify an unknown victim of the Green River Killer.

PNAS Papers on Chemotherapy-Induced Cardiac Injury Target, Viral Insertions, SMRT Methylation Profiling

In PNAS this week: target to reduce chemotherapy-induced cardiac injury, tool finds ancient endogenous RNA viruses, and more.

Should Also Work

Moderna reports its vaccine is effective against new SARS-CoV-2 strains, though it is also developing a booster, according to the New York Times.

Menu